Analysis of the cerebrospinal fluid can detect whether a person has Alzheimer's disease before symptoms appear. Researchers at the Sahlgrenska Academy at the University of Gothenburg, Sweden, have ...
(Nasdaq: CNSY) (“Cerenome” or the “Company ”), today announced the commercial launch of two new cerebrospinal fluid (CSF)-based molecular profiling tests, available to health care professionals in the ...
A new cost-effective workflow improves proteomic analysis of plasma and cerebrospinal fluid by optimizing protein depletion ...
The newly FDA-cleared tests can run on any of Roche’s Cobas immunoassay analyzers. Both are cerebrospinal fluid assays: They analyze CSF samples to measure the concentration of beta-amyloid and tau ...
SAN DIEGO, September 15, 2026--(BUSINESS WIRE)--A new innovation in the detection of MSA pathology is here. Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed ...
First CNSide payer agreement to include CNSide’s new CSF Molecular Profile tests alongside tumor cell enumerationExpands CNSide contracted payer ...
Blood tests for Alzheimer’s disease are now so accurate that a positive result, on its own, is reason enough for people who are suspected of having AD to start immunotherapy. So proffered Suzanne ...
Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological conditions, according to a new study that analyzed cryopreserved CSF samples ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results